Dr. Thomas P. Slavin Named Senior Vice President of Medical Affairs for Myriad Oncology

World News: . []

SALT LAKE CITY, Jan. 14, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has named Thomas P. Slavin, M.D., FACMG, DABMD, senior vice president of Medical Affairs at Myriad Oncology effective March 2, 2020. In this role, Dr. Slavin will provide medical and scientific leadership across Myriad's portfolio of molecular and companion diagnostic products and services for oncology. Dr. Slavin will report to Nicole Lambert, president of Myriad Oncology. 

“Thomas’ leadership in hereditary cancer makes him a great fit for Myriad Oncology,” said Ms. Lambert. “His expertise in clinical genetics and molecular diagnostics will help accelerate new opportunities for genetic testing and enable greater access to precision oncology for people with cancer.”

Dr. Slavin is triple-board-certified in clinical genetics, molecular diagnostics and pediatrics. Most recently, he served as assistant professor in the departments of Medical Oncology & Therapeutics Research and Population Sciences at City of Hope National Medical Center. He has served on National Comprehensive Cancer Network (NCCN) committees for both the genetics of and screening for colorectal cancer. He serves on three ClinGen expert working group committees for variant classification of breast, gastrointestinal and ovarian cancer predisposition genes. Focused on expanding genetics education for cancer care providers, Dr. Slavin has helped shape both the American Society of Clinical Oncology’s (ASCO) University as well as City of Hope’s hereditary genomics training program. He has an extensive publication history in the field of medical genetics, including 56 journal articles, 59 presentations at medical meetings and multiple book chapters. Dr. Slavin has been involved in multiple national cancer research grants, and was recently awarded a K08 grant from the National Institutes of Health (NIH). He received his medical doctorate and his bachelor’s degree from the University of South Florida in Tampa.

“I am excited to join Myriad Oncology and lead the medical team as we work to advance precision medicine in oncology,” said Dr. Slavin. ”Myriad is the leader in molecular diagnostics, and I am proud to be part of a team that is expanding access to genetic testing and bringing important new scientific advances to clinicians.”

Myriad, the Myriad logo, BART, BRAC, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, ForeSight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

More news and information about Myriad Genetics, Inc.

Published By:

Globe Newswire: 12:05 GMT Tuesday 14th January 2020

Published: .

Search for other references to "thomas" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2020. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us